papaverine has been researched along with mefloquine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bojkova, D; Ciesek, S; Cinatl, J; Claussen, C; Ellinger, B; Geisslinger, G; Gribbon, P; Keminer, O; Kuzikov, M; Reinshagen, J; Westhaus, S; Wolf, M; Zaliani, A | 1 |
1 review(s) available for papaverine and mefloquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for papaverine and mefloquine
| Article | Year |
|---|---|
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.
Topics: Antiviral Agents; Benzamidines; Caco-2 Cells; Cetylpyridinium; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Esters; Guanidines; Humans; Lopinavir; Mefloquine; Papaverine; SARS-CoV-2 | 2021 |